Cargando…
Current Approaches in NSCLC Targeting K-RAS and EGFR
The research and treatment of non-small cell lung cancer (NSCLC) have achieved some important advances in recent years. Nonetheless, the overall survival rates for NSCLC remain low, indicating the importance to effectively develop new therapies and improve current approaches. The understanding of th...
Autores principales: | Aran, Veronica, Omerovic, Jasminka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888213/ https://www.ncbi.nlm.nih.gov/pubmed/31739412 http://dx.doi.org/10.3390/ijms20225701 |
Ejemplares similares
-
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008) -
EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008) -
K-RAS4A: Lead or Supporting Role in Cancer Biology?
por: Aran, Veronica
Publicado: (2021) -
Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies
por: Meng, Ying, et al.
Publicado: (2023) -
Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance
por: Maity, Swastika, et al.
Publicado: (2020)